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ABSTRACT: A series of chalcone and heterocyclic isosteres, in which the enone moiety was replaced with an isoxazole and
pyrazole ring system, was synthesized and their aﬃnities for alpha synuclein (Asyn), amyloid beta (Aβ), and tau ﬁbrils were
measured in vitro. The compounds were found to have a modest aﬃnity and selectivity for Asyn versus Aβ ﬁbrils and low aﬃnity
for tau ﬁbrils. Insertion of a double bond to increase the extendable surface area resulted in an increase in aﬃnity and
improvement in selectivity for Asyn versus Aβ and tau ﬁbrils. The results of this study indicate that compound 11 is a secondary
lead compound for structure−activity relationship studies aimed at identifying a suitable compound for positron emission
tomography-imaging studies of insoluble Asyn aggregates in Parkinson’s disease.
■ INTRODUCTION
The accumulation of insoluble protein aggregates is the
hallmark feature of most neurodegenerative disorders. For
example, Alzheimer’s disease (AD) is characterized by the
formation of two diﬀerent protein aggregates, amyloid plaques
and neuroﬁbrillary tangles (NFTs).1 Amyloid plaques are
formed by the misprocessing amyloid precursor protein to form
Aβ1-42, and the misfolding of this protein from an alpha helix
to a beta pleated sheet causes aggregation to form ﬁbrils, which
precipitate in the form of amyloid beta (Aβ) plaques. NFTs are
caused by the ﬁbrillization of hyperphosphorylated tau, a
microtubule-associated protein, which is thought to be formed
later in the disease process than Aβ plaques. For many decades,
the identiﬁcation of patients having AD was not conﬁrmed until
autopsy, a diagnosis that was based on the density of amyloid
plaques and NFTs in various brain regions. There was a
breakthrough in the clinical characterization of AD with the
development of radiotracers such as [11C]PiB and [18F]-
ﬂorbetapir, which are capable of providing a measure of
amyloid plaques in living human brain in conjunction with
positron emission tomography (PET).2−4 More recent eﬀorts
have focused on the development of PET radiotracers for
imaging aggregated tau in NFTs, and PET-imaging studies have
conﬁrmed that NFTs are formed much later in the disease
process than Aβ plaques.5−7
A second neurodegenerative disease characterized by
insoluble protein aggregates is Parkinson’s disease (PD). In
this case, the protein alpha synuclein (Asyn), a highly abundant
protein in brain, is not degraded and leads to a similar
formation of beta pleated sheets and ﬁbril formation. The Asyn
ﬁbrils eventually form two diﬀerent insoluble protein
aggregates, Lewy bodies and Lewy neurites, which have been
used to characterize PD at the time of autopsy.8−10 Lewy
bodies and Lewy neurites are also found in another
Parkinsonian-like syndrome termed dementia with Lewy bodies
and in glial cell inclusion bodies in multiple system atrophy.
Taken collectively, these neurodegenerative disorders have
been termed “synucleinopathies” because they have as a
common feature the formation of insoluble protein aggregates
of ﬁbrillary Asyn.11
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The tremendous success in the application of Aβ and tau
imaging agents in the study of AD has led to an international
eﬀort to develop a PET radiotracer for imaging Asyn aggregates
in Lewy bodies, Lewy neurites, and glial cell inclusion bodies. A
limitation in the development of PET radiotracer for this
purpose has been the dearth of lead compounds to serve as a
starting point for structure−activity relationship (SAR) studies
aimed at developing an optimized probe for translational
imaging studies. Because Aβ and tau pathologies are often
observed in postmortem samples of PD brain, it is important
that a PET radiotracer for imaging Lewy bodies and Lewy
neurites displays high selectivity for aggregated Asyn versus Aβ
and tau.12 This topic has been discussed in greater detail in a
recent review.11
We previously reported the synthesis and in vitro character-
ization of a panel of indolinone−diene analogues as potent and
selective ligands for Asyn versus Aβ and tau ﬁbrils.13 A
limitation of this class of compounds is the tendency of some of
the analogues to isomerize into E,E and Z,E isomers and their
high lipophilicities, which limits their utility as a radioligand for
PET-imaging studies.
For the current study, we chose to investigate a series of
chalcone derivatives because the enone moiety serves as an
isosteric replacement of the diene group while avoiding the E,E
and Z,E isomerization problem observed with the indolinone−
diene analogues. Chalcone analogues have been previously
reported to bind to Aβ but had a low aﬃnity for Asyn.14,15 We
also replaced the indole ring system with a benzothiazole ring
system because our previous SAR study revealed that an
electron-deﬁcient ring such as the aza-indole system has a
higher aﬃnity for Asyn ﬁbrils relative to the indole ring system
(Figure 1; 1−3).13 The benzothiazole ring system is also
present in cyanine dyes that have been shown to bind to Asyn
ﬁbrils (Figure 1; T-284 and SH-516).16 Finally, we replaced the
enone moiety with an isoxazole and pyrazole ring system to
avoid the Michael-acceptor properties of the chalcone system.
We utilized thioﬂavin T (ThioT) competition assays to
characterize the binding aﬃnity, an approach we previously
utilized for phenothiazine and indolinone−diene compounds to
guide the identiﬁcation of lead compounds for radiolabeling
and further characterization.13,17,18 The results of in vitro
binding studies led to the identiﬁcation of compounds having a
higher aﬃnity for Asyn versus Aβ and tau ﬁbrils. Molecular-
modeling studies were also conducted to identify the properties
of the ligands contributing to this selectivity. Although the
compounds described in this report do not have the high
aﬃnity to serve as a PET radiotracer for in vivo imaging studies,
they could serve as secondary lead for further SAR studies.
■ RESULTS AND DISCUSSION
The synthesis of the target compounds involved a simple
condensation reaction with 2-acetylbenzothiazole and the
substituted benzaldehyde (Scheme 1). We chose to explore
only the 4-OCH3, 4-N(CH3)2, and 4-NO2 substituted
Figure 1. Structure of compounds reported to bind to Asyn ﬁbrils.13,16
Scheme 1. Synthesis of Chalcone Analoguesa
aReagents and conditions: (i) NaOH, CH3OH.
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compounds because our previous studies indicated that these
were preferred substituents in the indolinone−diene series.13 In
vitro binding studies revealed that the benzothiazole chalcone
analogues had only a modest aﬃnity for Asyn ﬁbrils and a
slightly higher aﬃnity for Aβ ﬁbrils (Table 1 and Supporting
Information Table). The calculated log P values were also
higher than those of the corresponding indolinone−diene
analogues, which is also an undesirable property for a PET
radiotracer for brain-imaging studies.
The next step in the process involved removal of the benz-
fused aromatic ring to make the corresponding thiazole
chalcone analogues (7, 8, and 9; Scheme 1). We were quite
surprised to see that this simple change in structure resulted in
an increase in aﬃnity for Asyn and improved selectivity for
Asyn versus Aβ and tau ﬁbrils. Of the three derivatives, the 4-
methoxy group had the highest potency for Asyn (Ki = 53 nM)
and the highest selectivity for Asyn versus Aβ and tau ﬁbrils.
The isosteric replacement of the enone moiety of compound
7 with a ﬁve-membered heterocyclic ring was also explored.
The rationale for this substitution was the publication of the
pyrazole analogue, anle138b (Figure 1), which was reported to
have a modest aﬃnity for Asyn ﬁbrils.19,20 Therefore, both the
pyrazole and isoxazole analogues of compound 7 were
synthesized and evaluated in vitro for binding to Asyn, Aβ,
and tau ﬁbrils (Scheme 2). The results of in vitro binding
studies revealed that the pyrazole (12) and isoxazole (10)
analogues had an aﬃnity for Asyn similar to that reported for
anle138b (Ki = 190 nM) and good selectivity versus Aβ and tau
ﬁbrils (Table 2). As a ﬁnal structural change, a double bond was
inserted between the central heterocyclic ring system and the 4-
methoxyphenyl ring. The synthesis of the target compounds is
shown in Scheme 2. Although the synthesis of the pyrazole
analogue resulted in the formation of a single isomer (13), the
Table 1. Ki Values (nM) of Chalcone Derivatives for Asyn,
Aβ, and Tau Fibrilsa
# Asyn Aβ tau log Pb
1c 61.1 ± 9.6 125.8 ± 42.6 169.0 ± 22.3 3.1
2c 40.7 ± 8.7 27.6 ± 4.8 53.7 ± 9.7 3.5
3c 11.5 ± 2.0 15.3 ± 5.5 35.0 ± 12.3 2.9
4 530.5 ± 64.3 353.0 ± 29.7 716.5 ± 58.7 4.3
5 906.0 ± 29.7 91.0 ± 12.7 NB 4.2
6 >500 89.0 ± 26.9 NB 4.3
7 53.0 ± 19.8 >500 >1000 2.9
8 95.5 ± 29.0 505.0 ± 49.5 401.5 ± 118.1 3.3
9 191.5 ± 3.5 404.0 ± 80.6 NB 2.5
aGraphs for the ThioT competition binding assays are shown in the
Supporting Information Table. bCalculated by ChemDraw Profes-
sional 15.1. cCompounds 1−3 are compounds 19−21 of Chu et al.13
Scheme 2. Synthesis of Isoxazole and Pyrazole Analoguesa
aReagents and conditions: (i) NaOH, CH3OH; (ii) KOH, CH3OH, NH2OH·HCl/reﬂux; (iii) NaH, tetrahydrofuran (THF), ethyl-4-
methoxybenzoate: (iv) NH2NH2·H2O, EtOH; (v) trimethylsilane (TMS)2NLi, THF, (E)-3-(4-methoxyphenyl)acryloyl chloride; (vi) NH2OH−
HCl, EtOH, 80 °C.
Table 2. Ki Values (nM) of Isoxazole and Pyrazole
Derivatives for Asyn, Aβ, and Tau Fibrils
# Asyn Aβ tau log Pa
10 133.5 ± 78.5 >1000 >1000 3.03
11a,b 18.5 ± 9.2 91.5 ± 58.7 >1000 3.54
12 162.5 ± 41.7 >1000 >1000 2.95
13 59.0 ± 11.3 327.0 ± 76.4 >1000 3.47
aCalculated by ChemDraw Professional 15.1.
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corresponding isozazole analogue was obtained as a 50:50
mixture of isomers (11a,b). In each case, the addition of the
double bond resulted in an improvement in aﬃnity for Asyn
and Aβ ﬁbrils but not tau ﬁbrils (Table 2). However, both
compounds had a 4-5-fold higher selectivity for Asyn versus Aβ
ﬁbrils.
Molecular-modeling studies were conducted to identify the
molecular properties important for binding to Asyn ﬁbrils. The
modeling studies described below were performed on 11b
because subsequent in vitro studies of the tritiated analogue
were conducted with this isomer. The structural conformation
of 11b and in vitro binding studies of [3H]11b will be reported
separately.
The three-dimensional geometric and chemical properties
from the minimized structure of each compound are shown in
Table 3. The measurement of geometric properties, including
dihedral angles Ø and ψ and angle θ are illustrated in Figure 2.
A small dihedral angle Ø (−179.1° to −180°) was observed
between the central enone/5-member heteroaromatic group
and the thiazole/benzothiazole group in compounds 4−13.
The dihedral angle ψ for the chalcone series (4−9, ψ = −35.6°
± 1.1°) was greater than those for the isoxazole and pyrazole
analogues (10−13, ψ = 0.2° ± 0.3°), indicating that the
isoxazole and pyrazole analogues are relatively ﬂat compared to
the chalcone analogues. The angle θ represents the linearity in
shape among the central group and the pendant aromatic
groups in each compound. The angle θ for compounds 10−13
(θ = 156.3° ± 6.4°) was smaller than that for compounds 4−9
(θ = 130.4° ± 2.4°), suggesting that the isoxazole and pyrazole
analogues have a more linear geometry relative to the chalcone
Table 3. Three-Dimensional Geometric Characteristics and Chemical Properties from the Minimized Structure of an Individual
Compound
# Ø (°) ψ (°) θ (°) topological diameter (bonds) accessible surface area (Å2) polar surface area (Å2) shape attribute
4 −179.2 −36.4 128.1 13.0 529.4 39.7 19.0
5 −179.2 −35.5 128.1 13.0 558.3 32.7 20.0
6 −179.4 −36.2 128.2 13.0 519.0 81.2 20.0
7 −179.2 −36.0 132.5 11.0 459.4 38.7 15.1
8 −179.1 −35.1 132.6 11.0 488.3 32.7 16.1
9 −179.4 −36.0 132.6 11.0 449.0 81.2 16.1
10 −179.9 0.5 151.7 11.0 454.5 43.2 16.1
11b −179.9 0.4 160.6 13.0 508.9 43.2 18.1
12 −180.0 0.0 150.0 11.0 460.7 46.0 16.1
13 −180.0 0.0 162.8 13.0 514.4 46.0 18.1
Figure 2. Illustration of the geometric properties of the chalcone and heterocyclic analogues. Red labeled: dihedral angle, Ø; green labeled: dihedral
angle, ψ; blue labeled: angle, θ.
Figure 3. Three-dimensional structures of chalcone compound 7 and isoxazole compounds 10 and 11b. (a) Compound 11b shows a ﬂatter angle θ
and is closer to linear shape as compared to 7 and 10. The thiazole ring of compound 7 is in the reverse position to 10 and 11b. (b) View of 90°
rotation of each compound. A dihedral angle ψ = −36.0° is shown in compound 7. Compounds 10 and 11b were close to ﬂat. The distance of
hydrogen bond acceptors from the central group to the methoxy group is 8.44 Å for compound 7, shorter for cyclized compound 10 (7.72 Å), and
greater for compound 11b by the introduced double bond (9.98 Å). Red labeled: dihedral angle Ø. Green labeled: dihedral angle ψ.
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analogues. Overall, the isoxazole and pyrazole analogues are
relatively ﬂat and have a more linear geometry relative to the
chalcone analogues, resulting in a higher aﬃnity for Asyn ﬁbrils
(10−13 Ki = 18.5−162.5 nM vs Ki = 53.0−906.0 nM for 4−9)
and a better selectivity for Asyn versus Aβ ﬁbrils (5 to >7 folds
for 10−13 vs 0 to >9 folds for 4−9).
With respect to substitutions of the phenyl group in the
chalcone series, compounds with the dimethylamino group (5
and 8) showed a higher accessible surface area (4 vs 5: 529.4 vs
558.3 Å2; 7 vs 8: 459.4 vs 488.3 Å2) and a lower polar surface
area (4 vs 5: 39.7 vs 32.7 Å2; 7 vs 8: 38.7 vs 32.7 Å2) as
compared to the compounds with a methoxy group (4 and 7).
The nitro-containing compounds 6 and 9 have a lower
accessible surface area (6: 519.0 Å2, and 9: 449.0 Å2) and a
higher polar surface area (both 6 and 9 = 81.2 Å2). Although
the accessible and polar surface areas showed a trend in an
improved aﬃnity (Table 1) for Aβ ﬁbrils (4 vs 5: Ki = 353 vs 91
nM; 7 vs 8: Ki = >500 vs 505 nM) and a reduced aﬃnity for
Asyn ﬁbrils (4 vs 5: Ki = 531 vs 906 nM; 7 vs 8: Ki = 53 vs 96
nM) to the compounds with the methoxy group versus
dimethylamino group, the tendency did not consistently show
in the nitro-containing compounds. This suggests that these
properties may not be good indicators to improve aﬃnity or
selectivity for Asyn, Aβ, or tau ﬁbrils.
The isoxazole compound 10, pyrazole compound 12, and
chalcone compound 7 shared the same topological diameter
(i.e., 11 bonds), had a similar shape attribute (7, 10, and 12 =
15.1, 16.1, and 16.1), and a similar range of accessible surface
area (7, 10, and 12 = 459.4, 454.5, and 460.7 Å2). There was a
tilt in angle ψ of the benzene ring in 7 (ψ = −36.0°) (Figure
3b), whereas this angle was close to zero in compounds 10 (ψ=
0.5°) and 12 (ψ = 0.0°). The thiazole ring in the minimized
structure was in the opposite orientation for chalcone analog 7
relative to the cyclic compounds 10 and 12. Therefore, the
hydrogen bond acceptors or donor (i.e., NH of the pyrazole
ring) are located on the same side of 10 and 12. This may be
one of the factors that resulted in the aﬃnity (Table 2) of 10
(Ki = 134 nM) and 12 (Ki = 163 nM) for Asyn ﬁbrils being
lower than that of 7 (Ki = 53 nM).
Introduction of a double bond into the isoxazole and
pyrazole derivatives increased the accessible surface area (10
and 12 = 454.5−460.7 Å2 vs 508.9−514.4 Å2 for 11b and 13)
and topological diameter (10 and 12 = 11.0 bonds vs 13.0
bonds for 11b and 13), which resulted in an improvement in
aﬃnity for both Asyn (10 and 12 vs 11b and 13, Ki = 134−163
vs 19−59 nM) and Aβ ﬁbrils (10 and 12 vs 11b and 13, Ki =
>1000 vs 92−327 nM) (Table 2).
We also observed that the intramolecular distance between
hydrogen bond acceptors may be one of the factors inﬂuencing
the binding aﬃnity to Asyn, that is, for chalcone analog 7, the
distance between the carbonyl oxygen and the oxygen of the
methoxy group was 8.44 Å, and its aﬃnity for Asyn was 53 nM.
For the isoxazole compound 10, the distance between the
isoxazole oxygen and the oxygen of the methoxy group was
shorter at 7.72 Å, and its aﬃnity for Asyn was lower (Ki = 134
nM). The distance between the isoxazole oxygen and the
oxygen of the methoxy group in analog 11b was 9.98 Å, and its
aﬃnity for Asyn was 19 nM. Therefore, the rank order potency
for binding to Asyn was 11b > 7 > 10, which had the same
order for distance between the two diﬀerent oxygen atoms
(9.98 > 8.44 > 7.72 Å) (Figure 3b). Ono et al.15 have studied
the diﬀerent lengths of the double bonds in chalcone analogues;
it also showed the diﬀerent distances between the carbonyl
oxygen and the nitrogen of dimethylamino. An extension of the
molecular length increased the binding aﬃnity for Asyn ﬁbrils,
but no inﬂuence for Aβ ﬁbrils, although in our study, the
binding aﬃnities for Aβ ﬁbrils were also improved from Ki >
1000 nM (10) to Ki = 91.5 nM (11) when the intramolecular
distance between hydrogen bond acceptors increased. This may
be caused by the length diﬀerences of the β-sheets in Asyn, Aβ,
and tau ﬁbrils. Additionally, it may be due to the binding mode
diﬀerences between ligands and ﬁbrils. The hydrogen bond may
play a more important role in the binding aﬃnity for Asyn than
for Aβ or tau ﬁbrils. The observation is based on three of our
compounds; more SAR studies and investigation of the
interaction between ligands and ﬁbrils are needed for
understanding the inﬂuence of intramolecular distance between
hydrogen bond acceptors.
The results of the molecular-modeling studies indicate that
the molecular shape, topographical diameter, and orientation
and distance between H-bond acceptors are important in
determining the aﬃnity for Asyn ﬁbrils. The studies described
above have also led to the identiﬁcation of a novel compound,
11, that has a good aﬃnity for Asyn ﬁbrils and a modest
selectivity for Asyn versus Aβ ﬁbrils. This compound represents
a good lead structure for further SAR studies aimed at the
development of a PET radiotracer for imaging Asyn aggregates
in vivo with PET. Additional SAR studies of compound 11 are
currently ongoing in our group.
■ EXPERIMENTAL SECTION
Chemistry. Reagents were purchased from Sigma-Aldrich
and Fisher Scientiﬁc. Silica gel chromatography was carried out
on a Biotage Isolera Spektra One chromatograph system. All
synthesized compounds were analyzed and conﬁrmed to have
purity over 95% with a Waters Alliance LC−MS system.
Nuclear magnetic resonance (NMR) spectra were measured on
a Bruker 500 or 360 MHz spectrometer, as indicated. Chemical
shifts (δ values) were reported in ppm relative to TMS. For
multiplicity, s = singlet, d = doublet, t = triplet, and m =
multiplet. 1H NMR spectra data are presented as follows:
chemical shifts (multiplicity, coupling constants, and integra-
tion).
(E)-1-(Benzo[d]thiazol-2-yl)-3-(4-methoxyphenyl)-
prop-2-en-1-one (4).21 NaOH (60 mg, 1.5 mmol) was
dissolved in methanol (5 mL). 4-Methoxybenzaldehyde (150
mg, 1.1 mmol) was added. The mixture was kept stirring at
room temperature (rt) for 2 min. 2-Acetylbenzothiazole (177
mg, 1 mmol) was added slowly. The mixture was kept stirring
at rt for 15 min, and yellow crystals were formed. The mixture
was ﬁltered, and the solid was washed with methanol and
hexanes, yielding 4 as yellow crystals (80 mg, 61%).
Characterization was the same as reported.21
(E)-1-(Benzo[d]thiazol-2-yl)-3-(4-(dimethylamino)-
phenyl)prop-2-en-1-one (5).22 NaOH (80 mg, 2.0 mmol)
was dissolved in methanol (5 mL). 4-N,N-Dimethylaminoben-
zaldehyde (300 mg, 2.0 mmol) was added. The mixture was
kept stirring at rt for 2 min. 2-Acetylbenzothiazole (177 mg, 1
mmol) was added slowly. The mixture was kept stirring at rt
overnight. The red solution was diluted with water (20 mL)
and extracted with ethyl acetate (20 mL × 2). The organic layer
was dried over Na2SO4 and condensed. The residue was
puriﬁed two times with FC (hexanes/ethyl acetate 10:1−6:1),
and compound 5 was obtained as a red solid (50 mg, 17%). 1H
NMR (500 MHz, CDCl3): δ 3.07 (s, 6H), 6.72 (d, J = 9.0 Hz,
2H), 7.49−7.58 (m, 2H), 7.67 (d, J = 8.5 Hz, 2H), 7.86 (d, J =
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16.0 Hz, 1H), 7.99, (d, J = 8.0 Hz, 1H), 8.04 (d, J = 16.0 Hz,
1H), 8.21 (d, J = 8.5 Hz, 1H). 13C NMR (126 MHz, CDCl3): δ
40.19, 111.88, 114.79, 122.35, 125.13, 126.68, 127.11, 131.38,
137.36, 147.29, 152.23, 153.80, 169.44, 182.42. MS (ESI) m/z:
309 (M + H)+.
(E)-1-(Benzo[d]thiazol-2-yl)-3-(4-nitrophenyl)prop-2-
en-1-one (6). NaOH (60 mg, 1.5 mmol) was dissolved in
methanol (5 mL). 4-Nitrobenzaldehyde (250 mg, 1.66 mmol)
was added. The mixture was kept stirring at rt for 2 min. 2-
Acetylbenzothiazole (177 mg, 1 mmol) was added slowly. The
mixture was kept stirring at rt for 2 h. A slightly yellow solid
was formed. The mixture was ﬁltered, and the solid was washed
with methanol and then puriﬁed with FC (hexanes/ethyl
acetate 6:1), yielding compound 6 as slightly yellow crystals
(130 mg, 42%). 1H NMR (360 MHz, CDCl3): δ 7.55−7.64 (m,
2H), 7.90 (d, J = 8.3 Hz, 2H), 8.01−8.06 (m, 2H), 8.18−8.31
(m, 4H). 13C NMR (90 MHz, CDCl3): δ 122.52, 124.22,
124.42, 125.60, 127.21, 128.00, 129.49, 142.25, 149.07, 153.85.
MS (ESI) m/z: 311 (M + H)+.
(E)-3-(4-Methoxyphenyl)-1-(thiazol-2-yl)prop-2-en-1-
one (7). NaOH (100 mg, 2.5 mmol) was added to a solution of
4-methoxybenzaldehyde (272 mg, 2 mmol) in methanol (15
mL), and the mixture was stirred for 5 min at 0 °C. 2-
Acetylthiazole (254 mg, 2 mmol) was added dropwise in 15
min. The mixture was kept stirring at rt overnight. The mixture
was then diluted with H2O and extracted with ethyl acetate.
The organic layer was dried over Na2SO4 and condensed. The
residue was applied to FC (hexanes/ethyl acetate 3:1), yielding
7 as a slight yellow solid (120 mg, 24%). 1H NMR (500 MHz,
CDCl3): δ 3.86 (s, 3H), 6.94 (d, J = 8.8 Hz, 2H), 7.67−7.69
(m, 3H), 7.83 (d, J = 16.0 Hz, 1H), 7.99 (d, J = 16.0 Hz, 1H),
8.05 (d, J = 3.1 Hz, 1H). 13C NMR (126 MHz, CDCl3): δ
55.43, 114.44, 118.12, 126.16, 127.46, 130.85, 144.59, 145.77,
162.10, 169.02, 181.59. MS (ESI) m/z: 246 (M + H)+.
(E)-3-(4-(Dimethylamino)phenyl)-1-(thiazol-2-yl)prop-
2-en-1-one (8). NaOH (100 mg, 2.5 mmol) was added to a
solution of 4-N,N-dimethylaminobenzaldehyde (300 mg, 2
mmol) in methanol (15 mL), and the mixture was stirred for 5
min at 0 °C. 2-Acetylthiazole (254 mg, 2 mmol) was added
dropwise in 15 min. After the addition, the mixture was diluted
with H2O and extracted with ethyl acetate. The organic layer
was dried over Na2SO4 and condensed. The residue was
applied to FC (hexanes/ethyl acetate 5:1), yielding 8 as a slight
yellow solid (130 mg, 25%). 1H NMR (500 MHz, CDCl3): δ
3.05 (s, 6H), 6.68 (d, J = 8.5 Hz, 2H), 7.61−7.65 (m, 3H), 7.73
(d, J = 8.0 Hz, 1H), 7.98−8.03 (m, 2H). 13C NMR (126 MHz,
CDCl3): δ 40.08, 111.72, 114.98, 122.54, 125.61, 131.14,
144.41, 146.96, 148.72, 152.39, 169.86, 181.34. HRMS m/z
(ESI): calcd for C14H15N2OS
+ [M + H]+, 259.0900; found
259.0905.
(E)-3-(4-Nitrophenyl)-1-(thiazol-2-yl)prop-2-en-1-one
(9). NaOH (160 mg, 4 mmol) was added to a solution of 4-
nitrobenzaldehyde (302 mg, 2 mmol) in methanol, and the
mixture was stirred for 5 min at 0 °C. 2-Acetylthiazole (254 mg,
2 mmol) was added dropwise in 15 min. After the addition, the
mixture was diluted with H2O and extracted with ethyl acetate.
The organic layer was dried over Na2SO4 and condensed. The
residue was applied to FC (hexanes/ethyl acetate 0−30%),
yielding 9 as a slight yellow solid (80 mg, 15%). 1H NMR (500
MHz, CDCl3): δ 7.76 (d, J = 3 Hz, 1H), 7.84 (d, J = 8.5 Hz,
2H), 7.97−8.08 (m, 3H), 8.27 (d, J = 8.5 Hz, 2H). 13C NMR
(126 MHz, CDCl3): δ 124.15, 124.53, 127.07, 129.30, 140.65,
142.18, 144.91, 148.72, 167.72, 180.09. MS (ESI) m/z: 261 (M
+ H)+.
3-(4-Methoxyphenyl)-5-(thiazol-2-yl)isoxazole (10).
Compound 7 (50 mg, 0.2 mmol) was dissolved in a solution
of KOH in methanol (23 mg in 3 mL). Hydroxylaminium
chloride (20 mg, 0.29 mmol) was added. The mixture was kept
reﬂuxing for 10 h. The mixture was diluted with ethyl acetate
and washed with H2O and brine. The organic layer was dried
over Na2SO4 and condensed. The residue was applied to FC
(hexanes/ethyl acetate 3:1%), yielding 10 as a slightly brown
solid (35 mg, 67%). 1H NMR (500 MHz, CDCl3): δ 3.88 (s,
3H), 7.00−7.02 (m, 3H), 7.49 (d, J = 3.5 Hz, 1H), 7.78 (d, J =
8.5 Hz, 2H), 7.98 (d, J = 3.0 Hz, 1H). 13C NMR (126 MHz,
CDCl3): δ 55.43, 96.31, 114.51, 119.76, 120.88, 127.56, 143.69,
158.77, 161.41, 171.09. HRMS m/z (ESI): calcd for
C13H11N2O2S
+ [M + H]+, 259.0536; found, 259.0540.
2-(5-(4-Methoxyphenyl)-1H-pyrazol-3-yl)thiazole (12).
Sodium hydride (480 mg, 20 mmol) was suspended in THF (2
mL). A solution of ethyl-4-methoxybenzoate (900 mg, 5 mmol)
in THF (2 mL) was added, and the mixture was heated to 60
°C. After dropwise addition of a solution of 2-acetylthiozole
(254 mg, 2 mmol) in THF (2 mL), stirring was continued for
16 h at 60 °C. The solution was poured into ice-old aqueous
HCl (1 M, 25 mL), and the mixture was extracted with
dichloromethane (DCM) (20 mL × 2). The organic layer was
dried over Na2SO4 and condensed under reduced pressure. The
residue was applied to FC (DCM/CH3OH 10:1), yielding 14
as a slightly yellow solid (110 mg, 21%). 1H NMR (500 MHz,
CDCl3): δ 3.88 (s, 3H), 6.97 (d, J = 8.5 Hz, 2H), 7.22 (s, 1H),
7.65 (d, J = 3.0 Hz, 1H), 7.98−8.13 (m, 3H), 16.10 (s, 1H). 13C
NMR (126 MHz, CDCl3): δ 55.51, 92.04, 114.09, 124.83,
126.49, 129.48, 144.63, 163.60, 166.53, 179.19, 183.01. MS
(ESI) m/z: 262 (M + H)+.
Compound 14 (78 mg, 0.3 mmol) was dissolved in ethanol
(5 mL), and the mixture was brought to reﬂux. Hydrazine
hydrate (0.5 mL) dissolved in ethanol was added to the
reﬂuxed solution. The mixture was kept reﬂuxing for 2 h. The
mixture was condensed and partitioned between DCM and
water. The organic layer was separated and dried over Na2SO4
and then condensed under reduced pressure. The residue was
applied to FC (hexanes/ethyl acetate 6:1−3:1), yielding 12 as a
colorless solid (45 mg, 58%). 1H NMR (500 MHz, CDCl3): δ
3.83 (s, 3H), 6.92 (d, J = 8.0 Hz, 2H), 7.00 (s, 1H), 7.31 (d, J =
3.0 Hz, 1H), 7.62 (d, J = 8.0 Hz, 2H), 7.86 (d, J = 3.0 Hz, 1H).
13C NMR (126 MHz, CDCl3): δ 55.73, 100.59, 114.38, 118.67,
126.95, 137.94, 143.14, 159.94. MS (ESI) m/z: 258 (M + H)+.
(2Z,4E)-3-Hydroxy-5-(4-methoxyphenyl)-1-(thiazol-2-
yl)penta-2,4-dien-1-one (15). A solution of 1-(thiazol-2-
yl)ethan-1-one (1.83 mL, 17.6 mmol) in THF (50.0 mL) was
cooled to −78 °C, and 1 M lithium bis(trimethylsilyl)amide in
THF (LiHMDS, 19.4 mL, 19.4 mmol) was added dropwise and
stirred at −78 °C for 1 h. To the reaction mixture was added
(E)-3-(4-methoxyphenyl)acryloyl chloride (3.52 g, 21.2 mmol)
in THF (20.0 mL) dropwise at the same temperature and
stirred at the ambient temperature for 3 h. After the reaction,
the reaction mixture was diluted with saturated NH4Cl (aq)
(200 mL) and extracted with EtOAc (150 mL × 2). The
combined organic layer was washed with H2O (200 mL), dried
over anhydrous Na2SO4, and concentrated. The crude
compound was dissolved in methanol and crystallized at 4
°C. The precipitate was ﬁltered and washed with cold methanol
which gave 15 (2.40 g, 47%) as a yellow solid. 1H NMR (360
MHz, CDCl3): δ 3.86 (s, 3H), 6.53 (d, J = 15.8 Hz, 1H), 6.75
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(s, 1H), 6.94 (d, J = 8.8 Hz, 2H), 7.53 (d, J = 8.7 Hz, 2H), 7.66
(s, 2H), 7.68 (d, J = 15.8 Hz, 1H), 8.02 (d, J = 3.0 Hz, 1H).
(E)-2-(3-(4-Methoxystyryl)-1H-pyrazol-5-yl)thiazole
(13). To a solution of (2Z,4E)-3-hydroxy-5-(4-methoxyphen-
yl)-1-(thiazol-2-yl)penta-2,4-dien-1-one (15, 1.00 g, 3.48
mmol) in EtOH (20.0 mL) was added NH2NH2−H2O (348
mg, 6.96 mmol) and stirred with reﬂux at 80 °C for 3 h. The
reaction mixture was cooled down to the ambient temperature
and EtOH was removed in vacuo. The crude compound was
puriﬁed by FC (hexanes/ethyl acetate 2:1), which gave 13 (500
mg, 51%) as a yellow solid. 1H NMR (500 MHz, DMSO-d6): δ
3.77 (s, 3H), 6.91 (s, 1H), 6.95−6.98 (m, 3H), 7.23 (d, J = 16.6
Hz, 1H), 7.49 (d, J = 8.7 Hz, 2H), 7.65 (d, J = 3.2 Hz, 1H),
7.85 (d, J = 3.2 Hz, 1H), 13.31 (s, 1H). 13C NMR (126 MHz,
DMSO-d6): δ 55.16, 100.22, 112.81, 114.32, 119.22, 127.85,
128.80, 130.45, 142.87, 143.05, 146.94, 159.38, 161.69. MS
(ESI) m/z: 284 (M + H)+.
(E)-3-(4-Methoxystyryl)-5-(thiazol-2-yl)isoxazole and
(E)-5-(4-Methoxystyryl)-3-(thiazol-2-yl)isoxazole (11).
To a solution of (2Z,4E)-3-hydroxy-5-(4-methoxyphenyl)-1-
(thiazol-2-yl)penta-2,4-dien-1-one (15, 250 mg, 0.87 mmol) in
EtOH (5 mL) was added NH2OH−HCl (121 mg, 1.74 mmol)
and stirred at 80 °C for 3 h. The reaction mixture was cooled
down to the ambient temperature and EtOH was removed in
vacuo. The crude compound was puriﬁed by FC (hexanes/
ethyl acetate 3:1) which gave an approximately 1:1 mixture of
two isomers 11 (80 mg, 32%) as a colorless solid. 1H NMR
(500 MHz, DMSO-d6): δ 3.78 (s, 6H), 6.98 (d, J = 8.7 Hz,
2H), 6.99 (d, J = 8.7 Hz, 2H), 7.08 (s, 1H), 7.13 (d, J = 16.5
Hz, 1H), 7.17 (d, J = 16.5 Hz, 1H), 7.48 (d, J = 16.5, 1H), 7.54
(d, J = 16.5 Hz, 1H), 7.56 (s, 1H), 7.61−7.65 (m, 4H), 7.97 (d,
J = 3.1 Hz, 1H), 8.05 (d, J = 3.1 Hz, 1H), 8.08 (d, J = 3.1 Hz,
1H), 8.11 (d, J = 3.1 Hz, 1H). 13C NMR (126 MHz, DMSO-
d6): δ 55.20, 55.25, 98.70, 98.75, 110.45, 112.35, 114.31,
114.38, 122.60, 123.70, 127.78, 128.13, 128.77, 129.01, 135.44,
137.29, 144.06, 144.69, 153.32, 155.46, 158.31, 160.07, 160.33,
162.86, 162.92, 170.38. HRMS m/z (ESI): calcd for
C15H13N2O2S
+ [M + H]+, 285.0692; found, 285.0685.
Binding Assay. The Asyn, Aβ, and tau ﬁbrils used in this
study were prepared as previous described.13 Additional
characterization of the Asyn ﬁbril preparation including atomic
force microscopy imaging has also been previously reported.23
Thioﬂavin-T competition assay studies were also performed
following the protocol in a previous paper by Chu et al.13 In
brieﬂy, competition assays used a ﬁxed concentration (1 μM) of
Asyn, Aβ, or tau ﬁbrils, consisting of 3 μM, 50 nM, and 4 μM of
Thioﬂavin-T, respectively. The competitor reaction was diluted
in 30 mM Tris-HCl, pH 7.4, 0.1% bovine serum albumin and
added to the reactions in varying concentrations. The reactions
were incubated at room temperature for 1.5 h before
quantifying the bound ligand. Fluorescence was determined
in a BioTek plate reader using a 440/30 excitation ﬁlter and a
485/20 emission ﬁlter. Data were analyzed using GraphPad
Prism software (version 4.0) to obtain EC50 values by ﬁtting the
data to the one-site competitive binding equation. Ki values
were calculated from EC50 values using the equation Ki = EC50/
(1 + [radioligand]/Kd). The average and standard deviation of
Ki values were calculated from the results of two competition
assays for each ﬁbrils.
Molecular Modeling. All structures were drawn on
ChemDraw Profession 15.1 (PerkinElmer Informatics, Inc.)
and then imported to Chem3D Ultra 15.1 (PerkinElmer
Informatics, Inc.) to minimize individual structures by
MMFF94 force ﬁeld for further geometric characteristic and
chemical property measurements. Chem3D Ultra 15.1 program
was also applied to measure the chemical properties. Connolly
accessible surface area was calculated by the ChemPropStd
property module. Polar surface, topological diameter, and shape
attribute were measured by the molecular topology property
module. Three-dimensional geometric characteristics were
measured based on the minimized structures by using Visual
Molecular Dynamics program.24 As illustrated in Figure 2, the
dihedral angles Ø and ψ between the central group and the
pedant aromatic groups were measured to evaluate the torsion
degree of each compound. The angle θ among the central
group and the pendant aromatic groups was calculated to
measure the linearity in shape. A molecular visualization system
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